Category Archives: Ventricular Remodeling

INTRODUCTION Anthracycline is a group of chemotherapeutic drugs that are being actively used to treat broad types of cancer (1, 2), but the major clinical complication for these antibiotics is their dose-dependent cardiotoxicity (1). Several mechanisms have been proposed for anthracycline-induced cardiotoxicity (AIC), including topoisomerase II (coded by TOP2B) as a primary mediator (3). On the basis of these mechanisms, dexrazoxane, an iron chelator, has been successfully developed as the only U.S Continue reading →

The long-term risk for a venous thromboembolism (VTE) event was found to be associated with the occurrence of heart failure with preserved or reduced ejection fraction, and with left ventricular remodeling, according to a study published in the Journal of the American College of Cardiology. In this prospective, population-based study, the short- and long-term risk for a VTE event was assessed in patients enrolled in the Atherosclerosis Risk in Communities study Continue reading →

Objectives This study sought to assess if clinical phenogroups differ in comprehensive biomarker profiles, cardiac and arterial structure/function, and responses to spironolactone therapy. Previous studies identified distinct subgroups (phenogroups) of patients with heart failure with preserved ejection fraction (HFpEF). Continue reading →

BACKGROUND: The mortality rate during the acutemyocardial infarction(AMI) phase has substantially decreased, but post-AMI cardiac remodeling remains an important factor affecting patient prognosis. Continue reading →

Global Cardiac Restoration Systems Market: Overview The implication of cardiac restoration systems involves the left ventricular restoration and mitral valve restoration. Continue reading →

Both Insmed Incorporated (NASDAQ:INSM) and BioLineRx Ltd. Continue reading →

Female cyclists are at a lower risk of suffering Sudden Cardiac Death than male athletes, but women should still learn about ways to screen for heart problems before engaging in endurance sports. Dr Continue reading →

Global Cardiac Restoration Systems Market From TMRRs Viewpoint Decorated with a team of 300+ analysts, TMRR serves each and every requirement of the clients while preparing market reports. Continue reading →

Study Published in European Journal of Heart Failure Shows Significant and Sustained Improvement in Heart Function, Symptom Relief and Quality of Life Using Less Invasive Left Ventricular Enhancement Device BioVentrix, Inc., developer of the first less invasive system for left ventricular remodeling, today announced online publication of positive one-year results from its CE Mark study of the Revivent TC System in the European Journal of Heart Failure. The paper will be published in print in the January issue of the journal. Authors of the study, entitled "Less Invasive Ventricular Reconstruction for Ischemic Heart Failure" concluded, "Treatment with the Revivent TC System in patients with symptomatic heart failure results in significant and sustained reduction of left ventricular (LV) volumes and improvement of LV function, symptoms, and quality of life." They added, "The ability to achieve these results without the need for sternotomy or cardiopulmonary bypass is an important advance for the treatment of patients suffering from ischemic cardiomyopathy heart failure." The prospective, multicenter, single-arm study of 89 patients at 22 centers in 12 countries in the European Union was designed to evaluate the efficacy and safety of the Revivent TC System for scar exclusion in the heart, volume reduction, and reshaping of the LV in selected patients with ischemic cardiomyopathy (enlarged and weakened left ventricle with reduced capacity to pump blood after a heart attack) Continue reading →

Maggie L. Shaw Heart issues in patients with cancer and survivors can present themselves months or years after treatment Continue reading →